Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
numab.com is the official website of Swiss biotech company Numab Therapeutics AG. The company focuses on the R&D of next-generation immunotherapies and tumor immunology drugs, building its R&D pipeline centered on multispecific antibody biotherapeutic technology, while conducting R&D collaborations with multiple leading pharmaceutical companies around the globe. The website primarily targets biopharmaceutical industry practitioners, pharmaceutical investors, and industry partners, showcasing the company's technology platforms, R&D pipeline progress, latest partnership updates, and team information.
The website showcases two core in-house developed technology platforms: λ-Cap™ and MATCH™. It features a reproducible, modular process for multispecific antibody discovery, which delivers targeted improvements in efficacy, stability, and safety compared to traditional first-generation antibodies. The website also publicly shares progress on the company's in-house R&D pipeline: the lead candidate drug NM26 targets atopic dermatitis, and there are also ongoing programs for indications including inflammatory bowel disease. It also details collaboration milestones with pharmaceutical companies such as Boehringer Ingelheim, and multiple partnered programs have now advanced to the preclinical development stage. In addition, the website provides complete information on the management team and board of directors, allowing investors to easily review the team's background.
This website is best suited for researchers in the biopharmaceutical industry, public and private market pharmaceutical investors, and partners in the biologic drug sector. General users cannot obtain directly usable drugs or services from this site. The website is fully accessible directly in mainland China, no VPN proxy is required. All content on the official website is in English, with no Chinese interface available.
As the official website of a biopharmaceutical R&D company, numab.com features clear, standardized information disclosure that fully showcases the company's core value and progress, which aligns perfectly with the characteristics of the industry. However, the company's pipeline has not yet reached commercialization, and it offers no practical services for the general public. My overall rating is 6 out of 10.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on numab.com official site.
numab.com is an Switzerland Health provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of China direct-connect friendly. Click "Visit Official Site" to reach numab.com directly.